|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 CAD | 0.00% |
|
0.00% | 0.00% |
| 26/01 | Optimind Pharma Reaches Agreement On Debenture Conversion | MT |
| 10/01 | Optimind Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023 | CI |
Optimind Pharma Corp. reported earnings results for the full year ended February 28, 2023. For the full year, the company reported sales was CAD 0.170113 million.
Net loss was CAD 3.08 million. Basic loss per share from continuing operations was CAD 0.04.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 4L | |
| +7.52% | 11TCr | |
| +11.38% | 11TCr | |
| -12.64% | 2.22TCr | |
| +0.44% | 2.23TCr | |
| -4.18% | 1.94TCr | |
| -37.85% | 1.79TCr | |
| -8.58% | 1.72TCr | |
| +37.41% | 1.25TCr | |
| -23.95% | 834.13Cr |
OPTIMIND PHARMA CORP. 
